Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPC


Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium, Axel Merseburger, MD, PhD, chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, discussed the PRESIDE trial (NCT02288247) of enzalutamide (Xtandi) vs matched placebo plus docetaxel and prednisone for men with progressive metastatic castration-resistant prostate cancer. The study was conducted to determine a continued benefit of the androgen receptor inhibitor after disease progression.


The PRESIDE trial showed the clinical benefit of continuing enzalutamide to post-progression [treatment]. This trial was a randomized phase 3b trial in advanced metastatic castration-resistant prostate cancer, with the primary end point progression-free survival [PFS].

Besides the primary end point of PFS which was met with a 28% benefit for the combination of enzalutamide, docetaxel, and prednisone compared with the placebo, docetaxel, and prednisone [HR, 0.72; 95% CI, 0.53-0.96; P = .027]. We could demonstrate that there was a greater decrease in PSA from baseline to week 13 in the enzalutamide group at –37.12% compared with 9.11% in the placebo group.


Merseburger A, Attard G, Boysen G, et al. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. J Clin Oncol. 2022;40(suppl 6):15. doi: 10.1200/JCO.2022.40.6_suppl.015

Related Videos
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Expert on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Expert on prostate cancer
Expert on prostate cancer
Related Content